Radiopharmaceutical Discovery

The research interests of the lab encompass PET and SPECT radiotracer development of oncology, brain and heart agents. This emphasis includes the design and evaluation of alicyclic and branched chain amino acids for in vivo mapping of intracranial and systemic tumors, cocaine analogs for in vivo study of the dopamine, serotonin, and norepinephrine reuptake sites in neurodegenerative disease, psychiatric and addictive disorders, heterocyclic analogs for in vivo mapping of CRF1, oxytocin and vassopressin receptors in psychiatric disorders, oligosaccharides for imaging bacterial imaging infections and intercalating agents for imaging atherosclerotic plaque.

Research efforts have resulted in the translation of the first reported synthetic amino alicyclic acid radiolabeled with the PET radioelement fluorine-18 for imaging both intracranial tumors and prostate cancer in patients and the first high affinity and selective tropanes for in vivo mapping of serotonin reuptake sites in the brain.

- Mark Goodman, PhD
Endowed Chair in Imaging Sciences
Director, Radiopharmaceutical Discovery


Current Research

  • Fluorine-18 FACBC for imaging gliomas in humans
  • Fluorine-18 DNA intercalators for imaging atherosclerosis
  • Fluorine-18 alanine type amino acid transporter substrates for imaging prostate, breast and lung cancer
  • Radiolabeled CRF1 receptor antagonists for imaging the CNS thalamic pituitary axis and systemic tumors
  • Radiolabeled neurotensin receptor antagonists for imaging pancreatic cancer
  • Fluorine-18 monocarboxylic acids for tumor imaging
  • Fluorine-18 saccharides for imaging bacterial infections in implanted cardiac devices and prosthetic joints
  • Radiolabeled oxytocin and vasopressin receptor antagonists for studying social behavior

Highlights and Accomplishments

The Society of Nuclear Medicine Paul C. Aebersold Award
Mark M. Goodman, PhD
Endowed Chair for Imaging Sciences
Professor of Radiology

Dr. Goodman was selected to receive the prestigious 2012 Paul C. Aebersold Award. Every year, The Society of Nuclear Medicine (SNM) Paul C. Aebersold Awards Committee selects an individual as the recipient of the Paul C. Aebersold Award for Outstanding Achievement in Basic Science applied to Nuclear Medicine. The Aebersold Award is named for Paul C. Aebersold, a pioneer in the biologic and medical application of radioactive materials and the first director of the Atomic Energy Commission's Division of Isotopes Development at Oak Ridge.

Recent Publications

Contact Information

Donna Kicullen
Research Project Coordinator
Phone: 404 712-1153